Can Magic Mushrooms Help Treat Cocaine Dependence? A Small Clinical Trial Offers Real Hope

The short answer

Can magic mushrooms help treat cocaine dependence? A new randomized clinical trial suggests that psilocybin—the primary psychedelic compound associated with magic mushrooms—may help some people with cocaine use disorder reduce their cocaine use, remain abstinent longer and lower their risk of relapse.

That is genuinely exciting. It is not, however, proof that eating mushrooms at home cures addiction.

The study involved only 40 adults, and psilocybin was administered once in a carefully screened, professionally supervised setting alongside weeks of structured psychotherapy. The results should be understood as promising early clinical evidence for psilocybin-assisted therapy, not an endorsement of unsupervised psychedelic use.

Still, for a disorder with no medication approved by the U.S. Food and Drug Administration, even an early positive signal matters.

Why cocaine use disorder is so difficult to treat

Cocaine use disorder is a medical condition characterized by persistent cocaine use despite serious consequences. It can affect physical health, mental health, employment, finances, relationships and nearly every other part of a person’s life.

Treatment can include cognitive behavioral therapy, contingency management, peer support and other behavioral interventions. These approaches can help, but relapse remains common, and there is currently no FDA-approved medication specifically for cocaine use disorder.

That treatment gap is one reason researchers have become interested in psychedelics. Rather than functioning like a daily maintenance medication, a psychedelic session may temporarily make entrenched patterns of thought and behavior more flexible. In theory, that period of increased psychological openness could make therapy more effective and help a person reconsider habits that previously felt automatic or impossible to change.

That remains a working scientific theory—not a settled explanation—but the new trial gives researchers a stronger reason to investigate it.

What the psilocybin and cocaine study actually tested

The randomized clinical trial was conducted at the University of Alabama at Birmingham and published in JAMA Network Open in May 2026. Researchers enrolled 40 adults with cocaine use disorder who wanted to stop using cocaine.

Participants were divided evenly into two groups:

One group received a single oral dose of psilocybin at 25 milligrams per 70 kilograms of body weight.
The comparison group received 100 milligrams of diphenhydramine, an antihistamine used as an active placebo.

The study was described as quadruple-blind, meaning participants, therapists, outcome assessors and independent statisticians were intended to remain unaware of the assignments. Everyone received a manual-based psychotherapy program incorporating cognitive behavioral treatment for approximately one month before and one month after the all-day dosing session.

This point cannot be emphasized enough: the intervention was not simply psilocybin. It was preparation, a supervised all-day drug session, psychotherapy and post-session integration.

Researchers then followed participants for 180 days and evaluated three central outcomes: the percentage of cocaine-abstinent days, the likelihood of complete abstinence and the amount of time before a first cocaine lapse. Self-reports were checked with urine testing.

What did the trial find?

Compared with participants who received the active placebo, those assigned psilocybin had:

A significantly higher percentage of cocaine-abstinent days
Greater odds of remaining completely abstinent
A substantially lower risk of a cocaine lapse during follow-up

The reported hazard ratio for a cocaine lapse was 0.28. In ordinary language, the psilocybin group experienced a markedly lower risk of lapse over the observation period than the placebo group.

The study also reported that six of the 20 people assigned psilocybin achieved complete cocaine abstinence during the follow-up period, compared with none of the 20 assigned placebo. Four participants were lost to follow-up, leaving 36 who completed assessments through day 180.

No serious adverse events occurred. Reported effects during or after the psilocybin session included temporary increases in blood pressure, emotional distress, crying and headache. These details matter because “safe in a screened clinical trial” is not the same as “risk-free for everyone.”

Why this study is especially important

There are several reasons the trial deserves attention beyond the headline.

First, this was a randomized, placebo-controlled study rather than an online survey or a collection of personal stories. Randomized trials provide a much stronger method for comparing an experimental intervention with a control condition.

Second, the participants better represented some of the people most affected by cocaine use disorder than participants in many earlier psychedelic studies. Thirty-three of the 40 participants were Black, 65 percent reported annual incomes of $20,000 or less, and the median age was 50. Psychedelic research has often struggled with a lack of racial and socioeconomic diversity, so this is a meaningful feature of the trial.

Third, the improvements continued for months after a single psilocybin session. Psilocybin leaves the body far sooner than that, suggesting that any durable benefit would likely involve psychological, behavioral and perhaps neurobiological changes rather than a direct drug effect lasting six months.

How might psilocybin help interrupt addiction?

Researchers do not yet have one proven answer. Several mechanisms may overlap.

Greater psychological flexibility

Addiction often involves deeply reinforced routines: triggers create cravings, cravings narrow attention, and familiar behavior follows. Psilocybin may temporarily loosen rigid patterns and help people view their lives, choices and identities from a different perspective.

A more powerful therapeutic window

The psychedelic experience can be emotionally intense and personally meaningful. Within a properly supported treatment program, that experience may give therapists and participants material they can explore during integration sessions. Insight alone is not recovery, but insight combined with new skills and continued support may help create behavioral change.

Changes in self-narrative

People living with addiction can become trapped in beliefs such as “this is simply who I am” or “I will always relapse.” Some psychedelic research suggests that profound experiences may weaken those fixed narratives and increase a sense of connection, meaning or self-efficacy.

Effects on brain networks and plasticity

Psilocybin acts primarily through serotonin 2A receptors and temporarily changes communication among brain networks. Scientists are studying whether this state promotes forms of neuroplasticity or makes established patterns easier to revise. It is an intriguing hypothesis, but the precise relationship between psychedelic brain effects and long-term recovery remains under investigation.

Why the results do not prove that psilocybin is a cure

The findings are encouraging, but several limitations prevent sweeping conclusions.

The study was small

With only 40 participants, the trial can identify a promising signal but cannot tell us how well the treatment would work across larger and more varied populations. The unusually wide confidence interval surrounding the abstinence odds estimate also reflects that uncertainty.

Participants were carefully selected

The trial excluded people with several conditions that can make psychedelic treatment riskier, including current hypertension, certain psychiatric disorders and a personal or family history of psychotic or bipolar disorders. Participants also wanted to quit cocaine. The outcome may not generalize to everyone with cocaine use disorder.

Blinding psychedelic trials is difficult

Even when an active placebo is used, the distinctive effects of a full psychedelic dose can make participants or clinicians suspect who received psilocybin. Expectations can influence outcomes, although the researchers reported that the active placebo performed reasonably well in maintaining uncertainty.

Therapy was part of both treatments

The study tested psilocybin in combination with structured psychotherapy. It did not establish that psilocybin alone produces the same results, and it cannot yet tell us which therapeutic elements are essential.

The research needs independent replication

The next step is not a rush toward self-treatment. It is a larger, adequately powered trial conducted across multiple sites, with broader participation, rigorous safety monitoring and longer follow-up.

This was not a “take mushrooms and hope for the best” experiment

Popular coverage sometimes compresses psychedelic research into a misleading formula: one dose, miraculous transformation, problem solved.

The real clinical model is far more involved. Participants are screened for physical and psychiatric risks. They prepare with trained professionals. The dosing environment is controlled. Support is available throughout the experience. Integration sessions help translate the experience into practical changes afterward.

Removing those safeguards changes the risk and may change the outcome. Psilocybin can produce panic, confusion, dangerous behavior in an uncontrolled environment and worsening symptoms in susceptible individuals. It can also interact with medical or psychiatric conditions and medications.

Psilocybin remains federally prohibited outside authorized research and limited state-regulated programs. It is not FDA-approved for cocaine use disorder.

What this could mean for the future of addiction treatment

For decades, society has often treated addiction as a moral failure deserving punishment. Science increasingly recognizes it as a complex health condition shaped by learning, trauma, environment, mental health, neurobiology and social circumstances.

Psychedelic-assisted therapy will not erase all of those factors. It cannot substitute for stable housing, continuing mental-health care, community support or evidence-based addiction services. But it could eventually become one tool within a much larger treatment system—especially for people who have not benefited from existing options.

The most interesting possibility is not that psilocybin simply suppresses a craving. It is that, under the right conditions, it may help a person create enough distance from an entrenched pattern to choose something different and then use therapy to make that change stick.

The bottom line

A small randomized clinical trial found that one supervised psilocybin session combined with structured psychotherapy was associated with more cocaine-abstinent days, a greater chance of complete abstinence and a lower risk of lapse over six months than psychotherapy paired with an active placebo.

Those results are important, particularly because there is no FDA-approved medication for cocaine use disorder. They are also preliminary. Forty participants are not enough to establish a new standard of care, and the controlled clinical protocol bears little resemblance to taking psychedelic mushrooms without medical screening or professional support.

So, can magic mushrooms help treat cocaine dependence? The most scientifically honest answer is: psilocybin-assisted therapy may be able to help, and researchers now have compelling early evidence to justify much larger trials.

That is not a cure. But in a field badly in need of better options, it is real hope worth studying.

Frequently asked questions

Is psilocybin approved to treat cocaine addiction?

No. Psilocybin is not FDA-approved for cocaine use disorder. Its use for this purpose remains experimental and is being studied in controlled research settings.

Did the participants take magic mushrooms?

The trial administered a measured dose of psilocybin in capsules, not retail or home-grown mushrooms. Mushroom potency can vary substantially, while clinical researchers use standardized dosing and controlled conditions.

Was one dose enough?

The experimental protocol used one psilocybin session, but participants also received preparation, cognitive behavioral therapy and integration support. The study does not show that a dose taken by itself would produce the same results.

Did everyone in the psilocybin group quit cocaine?

No. Six of 20 psilocybin participants achieved complete abstinence during follow-up. The group as a whole had better outcomes than the placebo group, but the treatment did not work completely for everyone.

Is it safe to use psilocybin while withdrawing from cocaine?

This study does not establish that unsupervised use is safe. Participants were medically and psychiatrically screened, abstained before dosing and were monitored by professionals. Anyone seeking help for cocaine use should consult a qualified health-care or addiction professional rather than attempting to reproduce the study alone.

Sources and further reading

Medical and legal disclaimer

This article is for educational purposes only and is not medical advice. It does not encourage illegal drug use or self-treatment. Psilocybin can carry serious psychological, medical and legal risks and is not appropriate for everyone. If you or someone you know is struggling with cocaine use, contact a qualified medical professional or the SAMHSA National Helpline at 1-800-662-HELP (4357). In an emergency, call 911.